What question did this study set out to answer?

To enhance the replication and immunogenicity of the non-replicating Tiantan strain-based vaccinia virus for use as a vaccine.

August 2, 2026Journal of VirologyOpen Access

Enhanced replication and immunogenicity of a genome-modified non-replicating vaccinia virus Tiantan strain for robust low-dose protection in mice

View Full Paper

Ask AI

Bookmark

To enhance the replication and immunogenicity of the non-replicating Tiantan strain-based vaccinia virus for use as a vaccine.
Constructed recombinant virus NTV-ΔF1L-C7L using CRISPR/Cas9 and homologous recombination.
Evaluated viral yields and immunogenicity in MRC-5 cells and mice.
Assessed immune responses and protection against lethal challenges.
NTV-ΔF1L-C7L yielded over 680-fold increase in viral production compared to parental NTV.
Achieved 100% protection against lethality from the vaccinia virus Western Reserve strain with low or single doses.
Induced stronger IgG and neutralizing antibody responses, with a significant Th1 cellular immune bias compared to parental NTV and VTT.

No takes yet. Share an insight, caveat, or question.

Randomized trial shows improved immunogenicity in mice, indicating potential as a novel vaccine against monkeypox.

Ren et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark